Mackay Shields LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

Mackay Shields LLC’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-39,200	Closed	-$1.03M	–	1262
2021 Q1	$1.03M	Sell	39,200 -25,000	-39%	-$699K	0.01%	988
2020 Q4	$1.61M	Buy	64,200 +24,000	+60%	+$517K	0.01%	925
2020 Q3	$838K	Buy	40,200 +9,600	+31%	+$218K	0.01%	1067
2020 Q2	$727K	Sell	30,600 -2,300	-7%	-$50.8K	0.01%	1112
2020 Q1	$592K	Hold	32,900	–	–	0.01%	1096
2019 Q4	$781K	Buy	+32,900	New	+$799K	0.01%	1111
2019 Q2	–	Sell	-9,853	Closed	-$346K	–	1501
2019 Q1	$346K	Hold	9,853	–	–	﹤0.01%	1252
2018 Q4	$328K	Buy	+9,853	New	+$424K	﹤0.01%	1237
2018 Q2	–	Sell	-90,500	Closed	-$4.14M	–	1293
2018 Q1	$4.14M	Buy	+90,500	New	+$3.78M	0.03%	549

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Mackay Shields LLC's SUPN Position: Q2 2021 in Review

Mackay Shields LLC sold out of Supernus Pharmaceuticals (SUPN) in Q2 2021, closing a stake of 39,200 shares — an estimated $1.03M sold.

Mackay Shields LLC first reported a position in SUPN in Q1 2018 and held it in 9 quarters. The position peaked at $4.14M in Q1 2018. 226 funds tracked by Wall St. Rank hold SUPN as of Q2 2021.

Mackay Shields LLC reported no remaining Supernus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Mackay Shields LLC sold 39,200 Supernus Pharmaceuticals shares in Q2 2021, an estimated $1.03M.
Mackay Shields LLC first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Mackay Shields LLC's Supernus Pharmaceuticals position peaked at $4.14M in Q1 2018.
226 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.